Mode
Text Size
Log in / Sign up
N/A Completed N=4,749,072

TB Innovation Project: A Pre- and Post- Implementation Assessment (TIPPI)

Tuberculosis · Pediatric
Source: ClinicalTrials.gov NCT03948698 ↗
Enrolled (actual)
4,749,072
Serious AEs
Results posted
Dec 2021
Primary outcomePrimary: Children Screened for TB — 4749072 Participants

Summary

This evaluation will be conducted in ten countries involved in the Catalyzing Pediatric TB Innovation (CaP-TB) project: Cameroon, Cote D'Ivoire, Democratic Republic of Congo, Kenya, Lesotho, Malawi, Tanzania, Uganda, Zimbabwe and India. The CaP-TB project is a project designed to use innovative methods and capacity building to strengthen the health systems of developing countries in terms of pediatric TB case detection, early accurate diagnosis and effective treatment. This project is funded by Unitaid and is implemented by Elizabeth Glaser Pediatric AIDS Foundation. EGPAF proposes to evaluate the implementation of CaP-TB in up to 450 sites in ten participating countries. This evaluation will assess the effects of CaP-TB innovative interventions on selected service delivery outcomes as compared to routine TB program in a sub-set of project sites in the ten countries.

Outcome Measures

OutcomeResultp-value
PRIMARY
Children Screened for TB
4749072
PRIMARY
Children With Presumptive TB
60250
PRIMARY
Children With Presumptive TB Referred for Lab-based TB Diagnosis
49022
PRIMARY
Children With Presumptive TB Tested Using GeneXpert
35554
PRIMARY
Children Initiated on TB Preventive Therapy
28762
PRIMARY
Children Completing TB Preventive Therapy
22590
PRIMARY
Children Diagnosed With Active TB
11078
PRIMARY
Children Initiated on TB Treatment
10834
PRIMARY
Children Achieving Treatment Success
6553
PRIMARY
TB Contacts Successfully Traced
20998
PRIMARY
TB Contacts Screened Negative for TB
37774
PRIMARY
TB Contacts Eligible for Preventive Therapy
19630

Eligibility Criteria

Inclusion Criteria

  • All pediatric TB patients (0-14 years of age) in CaP TB project sites in any of the 10 countries and receive TB screening (including screening, diagnosis and treatment for active TB, and provision of TB preventive therapy).
  • All pediatric TB patients (0-14 years of age) in CaP TB project sites in any of the 10 countries and receive TB diagnosis
  • All pediatric TB patients (0-14 years of age) in CaP TB project sites in any of the 10 countries and receive TB treatment for active TB
  • All pediatric TB patients (0-14 years of age) in CaP TB project sites in any of the 10 countries and receive TB preventive therapy

Exclusion Criteria

  • All pediatric TB patients who enter CaP TB project site in any of the 10 countries and who are above 15 years old
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03948698). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search